Genetically engineered expression of tumor-specific single chain antibody chimeric receptors (ch-Rec) on human T lymphocytes endow these cells with the parental monoclonal antibody (mAb) dictated tumor specificity and may be useful for clinical immuno-genetherapy. Therefore it was of importance to assess how the densities of tumor-specific receptors and tumor associated antigens (TAA), respectively, affect primary human T lymphocyte functions in relation to target cell susceptibilities to lysis. We therefore studied the functional balance between ch-Rec densities on human T lymphocytes and TAA on tumor cells. The gene construct encoding a ch-Rec derived from (1) a renal carcinoma cell (RCC) specific mouse mAb (G250), and (2) the human signal transducing Fc(⑀)RI ␥-chain was used. To obtain chRec HIGH-POS and ch-Rec LOW-POS T lymphocytes, two distinct retroviral vectors were used to introduce the gene constructs into primary human T lymphocytes. Levels of ch-Rec-
Introduction
Immune responses of T lymphocytes result from binding of T cell receptors (TCRs) on T lymphocytes to major histocompatibility complex (MHC)/antigen complexes on target cells. This binding leads to TCR-mediated signal transduction and activation of effector functions such as cytolysis and lymphokine production. 1, 2 The quantity, as well as quality, of the functional immune responses are affected by these TCR/antigen interactions. In a model system, T lymphocyte function was triggered in vitro by bispecific mAbs (bsmAbs), that interact with the CD3 complex on T lymphocytes and TAA on tumor cells, respectively. 3, 4 We and others showed that the level of activation of a T lymphocyte function, eg cytolysis, is positively correlated with the amount of bsmAb crosslinking TCRs and activation/target antigens, [5] [6] [7] and that following TCR/CD3 complex engagement with these antigens, TCRs on a single CTL that were triggered, become inactivated and degraded. 8, 9 Hence, CTLs serially use sets of TCR/CD3 complex for antigen engagement redirected T lymphocyte mediated tumor cell lysis, as well as lymphokine production were determined using RCC lines as target/stimulator cells, which express either no or increasing densities of the TAA. A functional and dynamic balance between ch-Rec densities on cytotoxic T lymphocytes (CTLs) on the one hand and TAA densities on RCCs on the other, was found. In short, ch-Rec HIGH-POS CTLs are triggered by TAA HIGH-POS as well as TAA LOW-POS RCCs to lyse tumor cells and produce (IFN-␥ and TNF-␣) lymphokine. In contrast, ch-Rec LOW-POS T lymphocytes are only triggered for cytolysis and lymphokine production by relatively TAA HIGH-POS RCCs. In conclusion, (1) the activation of T lymphocyte responses is co-determined by the expression levels of the ch-Rec on T lymphocytes and the TAA on tumor cells and (2) at relatively high T lymphocyte ch-Rec expression levels the CTLs lyse tumor cells with a wide range of TAA densities. Gene Therapy (2000) 7, 35-42. and can serially lyse multiple target cells. 8 However, T lymphocytes are not triggered to exert the full range of T cell functions at very low antigen densities. Also, different antigen densities or potencies result in different levels of TCR engagements and elicit the triggering of distinct effector functions. 8, [10] [11] [12] [13] The limited data that are available on the effect of low versus high TCR densities on antigen reactive T lymphocyte responses show a correlation with T lymphocyte activities. 11, 13, 14 A detailed understanding of the functional balance between TCR and TAA densities is therefore essential for the generation of optimally antitumor reactive T lymphocytes for cancer gene-immunotherapy now that adoptive transfer of tumor-specific CTLs to patients has demonstrated clinical benefit. However, specific CTLs from patients are difficult to isolate and cumbersome to expand to therapeutic numbers and this critically limits their clinical application. 15 Fortunately genetic programming of CD3 POS T lymphocytes specificity for TAA can be achieved by retroviral transfer of transgenes encoding for a tumor-specific mAb-derived ch-Rec. [16] [17] [18] Such ch-Rec consists of a mAb-based single chain antibody (scFv), coupled to a Fc(⑀)RI ␥-chain or CD3-chain, and these ch-Rec can functionally be expressed in the membrane of primary human T lymphocytes. [19] [20] [21] [22] [23] As for endogenous TCRs, binding of ch-Rec to relevant TAA results in activation of lymphocyte functions, eg target cell lysis and lymphokine production. [19] [20] [21] [22] [23] [24] The ch-Rec-mediated antigen binding is MHC-unrestricted and of high affinity. Moreover, adoptive transfer of genetically engineered ch-Rec POS CTLs has shown in vivo antitumor activity in mice. [25] [26] [27] We used a chimeric mAb-based receptor derived from the G250 mAb which specifically recognizes G250 TAA on RCCs. 28 Ch-Rec gene-transduced primary human CD3 POS T lymphocytes specifically: (1) recognize and lyse RCCs in an MHC-unrestricted fashion; and (2) produce lymphokines during interaction with RCCs, in spite of the fact that the ch-Rec density was too low to be detected by flow cytometric analysis. [21] [22] [23] In order to optimize the generation of primary human CTLs with genetically engineered tumor specificity and anti-tumor activity, we developed a retroviral vector system that produces high gene expression and high membrane expression of the ch-Rec by primary human T lymphocytes. 23 Because tumor cells in vivo express TAA at varying densities we determined how different densities of TAA tumor cells on the one hand and ch-Rec and T lymphocytes on the other affect the quantity and quality of T lymphocyte responses, which are important in anti-cancer immune activities.
We (Figure 3a) . In contrast, all relatively G250 TAA HIGH-POS RCCs were readily and equally well lysed by ch-Rec LOW-POS , ie no TAA dose response was observed (Figure 3a) .
Only a marginal level of lysis of G250 TAA
LOW-POS
RCCs by ch-Rec LOW-POS CTLs was observed (Figure 3b ). To exclude that G250 TAA LOW-POS SKRC17-2 cells showed a G250 TAA independent resistance to CTL lysis we added bsmAb CD3xG250 to the CTL/RCC mixture, beacuse bsmAbs cross-link CD3 on CTLs to G250 TAA on RCCs and trigger cytolysis. 29 G250 TAA LOW-POS RCCs were readily lysed by the ch-Rec LOW-POS CTLs sensitized with bsmAbs ( Figure 3b ). These results demonstrate that: (1) no 'overall resistance' explained the lack of lysis by ch-Rec LOW-POS CTLs; and (2) G250 TAA were expressed by SKRC17-2 RCCs, as already demonstrated by scatchart analysis (E Oosterwijk, personal communication). The G250 TAA HIGH-POS RCC cell lines showed increased densities of G250 TAA, but no TAA dose response was observed in combination with ch-Rec LOW-POS CTLs.
Ch-Rec HIGH-POS CTLs lyse G250 TAA LOW-POS as well as G250 TAA HIGH-POS RCCs The lack of significant lysis of G250 TAA LOW-POS RCCs by ch-Rec LOW-POS CTLs might be compensated for by using CTLs with increased ch-Rec surface densities. Therefore two retroviral vectors were used in parallel to introduce the same ch-Rec gene construct into human T lymphocytes derived from the same donor blood sample, LXSN and pSTITCH, respectively.
21,23
The ch-Rec 
/ml of G250 mAb followed by incubation with goat-anti-mouse PE conjugated (GAM-PE) (solid line) or by incubation with GAM-PE alone (dotted line). The difference in linear channel number is indicated for each sample (top right corner). Data are presented in histograms with relative cell number on the y-axis and relative fluorescence intensity (FL2) on the x-axis in log scale.
trations of blocking G250 mAb present the less G250 TAA is accessible for ch-Rec engagement as reflected by lower levels of target cell lysis ( Figure 5 ). This is further substantiated by the fact that lysis of TAA LOW-POS RCC by ch-Rec HIGH-POS CTL can be blocked by as little as 5 g/ml G250 mAb. This observed TAA dose-response curve for ch-Rec HIGH-POS CTL lytic activity confirms the doseresponse results presented in Figure 4a and b. From the results shown in Figure 5 (hatched bars) it can also be concluded that the more TAA are available for ch-Rec engagement, the higher the percent tumor cell lysis occurs per unit time, provided that the density of free TCRs on CTLs is not limiting, ie only in combination with ch-Rec HIGH-POS CTLs. Lysis of G250 TAA HIGH-POS RCCs by ch-Rec LOW-POS CTL was already blocked at 1 g/ml of G250 mAb. For comparison, only partial inhibition of lysis of G250 TAA HIGH-POS RCCs (SKRC17-3) by chRec HIGH-POS CTLs already required a 50 times higher concentration of G250 mAb.
Kinetics of tumor cell lysis do not depend on chimeric receptor density
Now that the functional balance between ch-Rec densities on CTLs and of TAA on tumor cells in relation to trig- and to produce cytokines that influence both their own performances as well as those of other cell types. 1 The different T lymphocyte effector responses that can be elicited, ie quality and magnitude of the response, depend on the density of the T lymphocyte receptors as well as on target cell density. [10] [11] [12] [13] [14] A detailed understanding of antigen-receptor/antigen relationships is important for the efficient generation and expansion of optimally reactive, tumor-specific CTLs for immunotherapy, since adoptive transfer of tumor-specific CTLs has shown significant clinical benefit. 15, 18 However, tumor-specific CTLs are difficult to isolate from cancer patients and their expansion to therapeutic numbers is time-consuming and the succes rate unpredictable.
Fortunately, genetic programming of T lymphocyte specificity is now possible by (retro)viral transfer of genes encoding mAb-based ch-Rec with a chosen TAA specificity. Engagement of such ch-Rec with TAA results in triggering of human T lymphocyte responses such as tumor cell lysis and tumor cell-triggered lymphokine production (Refs 19-24 and this paper). This molecular approach offers fundamental new opportunities for geneimmunotherapy. 18 In an earlier report on native TCR/CD3 complex functions we showed that individual human CTLs serially use sets of TCR/CD3 complexes to engage target TAA and that following signal transduction the disengaged TCR/CD3 complexes become inactivated and degraded. 8, 9 Prior unengaged TCRs on the same T lymphocyte can engage with antigens on new target cells. We proposed that this serial use of sets of TCRs may underlie the ability of individual CTL to serially lyse multiple target cells. 8 Further studies showed that already small numbers of target antigens can repeatedly trigger increasing numbers of TCRs on an individual CTL.
14, 30 The few reports available in the literature on the functional balance between TCR density and T lymphocyte response to antigens show that a decrease in TCR density results in reduced T lymphocyte responses. 11, 13 Hence, quality and quantity of T lymphocyte responses depend on and differ in (1) required thresholds of TCR occupancies; (2) antigen densities; and (3) antigen potencies. Different T lymphocyte responses may require
Figure 4 ch-Rec HIGH-POS CTLs can lyse TAA LOW-POS tumor cells. LXSN-HK␥ (a) and pSTITCH-HK␥ (b) gene-transduced human T lymphocytes expressing low or high ch-Rec receptor densities, respectively, were incubated with RCC SKRC17-1 (mock-transfected G250 TAA NEG RCC), SKRC17-2 (G250 TAA LOW-POS , gene-transfected RCC) and SKRC17-3 (G250 TAA HIGH-POS , gene-transfected RCC), and tested in a 4-h 51 Cr release assay. The specific 51 Cr release is depicted at different E:T ratios. Experiments were performed in triplicate, and the s.d. did not exceed 10%. Similar results were obtained from at least two independent experiments.
distinct signaling thresholds, in a T cell clone-specific hierarchy. [11] [12] [13] [14] 31 During the preparation of this manuscript we became aware of the data recently published by Alvarez and Russell, 32 who used a model system using Jurkat T cells with tetracycline-regulatable ch-Rec densities to study their level of IL-2 response as a function of plastic-coated antigen density. They concluded that Jurkat T cells can be engineered to discriminate Gene Therapy between different antigen densities allowing optimization of the Jurkat T cells' response to a fixed concentration of antigen. Here we indeed demonstrate that their conclusion holds for primary human T lymphocytes expressing ch-Rec specific for native TAA at the level of (1) specific tumor target cell lysis; and (2) lymphokine production (TNF-␣ and IFN-␥). We further investigated this functional balance between ch-Rec and TAA densities in relation to quantity and quality of CD8 T lymphocyte responses.
Figure 5 Gene-transduced T lymphocytes with low ch-Rec membrane density are more sensitive to inhibition of cytolysis with G250 mAb. RCCs SKRC17-3 and SKRC17-2 target cells were incubated with or without various concentration of G250 mAb. Cytolysis of SKRC17-1 (mock-transfected
Primary human CD3 POS T lymphocytes transduced with ch-Rec genes using the LXSN retroviral vector subsequently express very low densities of ch-Rec, not detectable by flow cytometric analysis using anti-idiotype mAbs. Presence of the ch-Rec was however readily detected in a sensitive 51 Cr release assay by measuring tumor-specific cell lysis, and by quantitative assessment of lymphokine production. 21 Here we determined the levels of both (1) 23 Now, aliquots of T lymphocytes from the same donors were gene transduced with the two viral vectors LXSN and pSTITCH. These two vectors yielded low and high expression levels of ch-Rec in the membrane of human T lymphocytes. Because no qualitative or quantitative differences in the gene transduction were observed between lymphocyte donors, the results obtained for one representative donor are presented. It appeared that G250 TAA LOW-POS RCCs were only lysed by ch-Rec HIGH-POS CTLs, not by ch-Rec LOW-POS CTLs. In contrast, G250 TAA HIGH-POS RCCs were lysed by both chRec LOW-POS and HIGH-POS CTLs. For the induction of the lymphokines INF-␥ and TNF-␣ the same functional balance between ch-Rec versus TAA densities was found. We excluded that the G250 TAA LOW-POS RCCs would in fact be: (1) G250 TAA NEG or (2) that these RCCs showed a G250 TAA independent overall resistance to CTL mediated lysis. The RCCs which were functionally labeled G250 TAA LOW-POS , in cytolytic assays, but G250 TAA NEG in flow cytometric analysis, were indeed shown to be G250 TAA LOW-POS in (1) scatchart analysis (E Oosterwijk, personal communication) and in (2) bsmAbmediated cytolysis assays (Figure 3b ). Differences in levels of lysis could not be due to alloreactivities generated in our T lymphocyte culture system since all SKRC cell lines used were cloned from one RCC line and hence MHC-identical.
We earlier reported that both bsmAb and ch-Recmediated TAA recognition and tumor cell lysis may involve adhesion molecules such as CD54 and CD58, depending on their cell surface densities.
6,7,22 Therefore we also needed to exclude that suboptimal levels of expression of CD54 and/or CD58 caused (1) the lack of ch-Rec-mediated lysis of G250 TAA LOW-POS RCC and/or (2) the lack of a G250 TAA dose response in combination ch-Rec HIGH-POS CTLs. Indeed, all cloned RCC lines tested expressed identical levels of CD54 and CD58 as determined by flow cytometry using the appropriate fluorochrome labeled mAbs. One could further speculate that only the minor 2% fraction of ch-Rec HIGH-POS CTL within the ch-Rec LOW-POS CTL population was responsible for the lysis of G250 TAA HIGH-POS RCCs. However, if this were true then, based on the E/T ratios presented and from cytotoxicity data shown in Figure 4 , by extrapolation it follows that at a 50-fold lower E/T ratio (of about 0.4) 70% lysis of RCCs could be induced. However, as shown in Figure 4 , for a level of 70% lysis of RCCs by chRec HIGH-POS CTLs, a 10-fold higher E/T ratio is required (ie about 4). Based on these considerations and calculations we propose that above a density threshold, TAA are spatially positioned in the membrane, that they can be optimally engaged by ch-Rec on CTLs. This hypothesis may find experimental support in our observations that for combinations of ch-Rec HIGH-POS CTLs where chRec density is not limiting clear TAA dose responses were observed: higher levels of lysis and lymphokine production are induced by higher TAA densities.
It is noteworthy that a relative over-expression of (ch)-Rec in combination with high antigen density can even induce T cell apoptosis rather then T cell activation. 32 In short, we showed that quantity and quality of the T lymphocyte responses is co-determined by (1) the ch-Rec density on CTLs and (2) ) (Nycomed, Oslo, Norway) and activated in Mix-med culture medium (78% RPMI 1640 buffered with bicarbonate (2 g/l) and HEPES (25 mm), 20% AIM-V (Gibco BRL, Paisley, UK), 2% heat inactivated human serum, 2 mm glutamine, 100 U/ml penicillin and 100 g/ml streptomycin), with 10 ng/ml OKT3 (Ortho, Beerse, Belgium) at a density of 0.5 × 10 6 cells/ml. Three days after activation, lymphocytes were washed and cultured in RPMI culture medium (RPMI 1640 buffered with bicarbonate (2 g/l) and HEPES (25 mm), 10% heat inactivated human serum, 2 mm glutamine, 100 U/ml penicillin and 100 g/ml streptomycin), supplemented with 360 IU/ml human recombinant IL-2 (rIL-2) (Chiron, Amsterdam, The Netherlands). 293T cells (kindly provided by Y Soneoka, Oxford, UK) were cultured in DMEM medium (BioWhittaker, Verviers, Belgium) containing 10% BCS (HyClone Laboratories, Logan, UT, USA), 100 U/ml penicillin and 100 g/ml streptomycin. The following cell lines were used as targets in cytotoxicity assays: three clones of MHC-identical SKRC17 RCC (SKRC17-1: mocktransfected, G250 TAA NEG RCC; SKRC17-2 and -3: G250 TAA cDNA transfected RCC), and four clones of MHCidentical SKRC59 cell line (SKRC59-1: G250 TAA NEG RCC; SKRC59-2, -3 and -4: G250 TAA cDNA transfected RCC) (kindly provided by E Oosterwijk, Nijmegen, The Netherlands). The antibodies used for FACS staining were: RCC antigen-specific G250 mAb (kindly provided by SO Warnaar, Centocor, Leiden, The Netherlands) 28 and anti-idiotype G250 mAb NUH-31 and NUH-82 (kindly provided by E Oosterwijk). 34 
Construction of ch-Rec retroviral vectors
The ch-Rec gene construct HK␥ was made as described elsewhere 21 and cloned into the retroviral vector LXSN 35 and pSTITCH. 23 For cloning into the vector pSTITCH, a NcoI site was introduced at the start codon using PCR.
ch-Rec gene transduction and selection of genetransduced human T lymphocytes Anti-CD3 activated T lymphocytes were gene-transduced with the either the LXSN or pSTITCH retroviral vector containing the ch-Rec construct. Gene transduction using LXSN was performed as described earlier. 21 In short, activated human T lymphocytes were co-cultivated for 3 days with the irradiated L(ch-Rec)SN-producing amphotropic packaging cell line PA317 in the presence of 360 IU/ml rIL-2 and 4 g/ml polybrene (Sigma, St Louis, MO, USA), followed by 9 days G418 selection. LXSNmediated ch-Rec transduction generates ch-Rec LOW-POS T lymphocytes. For pSTITCH gene transduction, retroviral particles were generated after transfection of 293T cells with 20 g of pHIT60, pCOLT-GALV and pSTITCH(chRec) retroviral vector by using CaPO 4 transfection. 23 
Gene Therapy
After 24 h, transfected cells were irradiated (25 Gy) and co-cultured for 3 days with 0.5 × 10 6 anti-CD3 activated human T lymphocytes/ml. Co-cultivation was performed in RPMI culture medium (RPMI 1640 buffered with bicarbonate (2 g/l) and HEPES (25 mm), 10% heat inactivated human serum, 2 mm glutamine, 100 U/ml penicillin and 100 g/ml streptomycin) supplemented with 360 IU/ml rIL-2 and 4 g/ml polybrene. ch-Rec POS human T lymphocytes were purified by using immunomagnetic isolation with NUH-31 mAb. 36 Gene-transduced human T lymphocytes were expanded in the presence of feeder cells as described previously. 37, 38 Flow cytometry The membrane expression of G250 TAA on RCC cells and ch-Rec on human T lymphocytes was measured by indirect immunofluorescence and flow cytometry on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA). Cells were washed in PBS containing 1% BSA (PBS/BSA) and resuspended in 50 l of PBS/1% BSA. Fifty microliters of the diluted mAb was added and incubated for 30 min at 4°C. Cells were washed once in PBS/1% BSA and the second step antibody goat-antimouse Ig PE conjugated was added for 30 min at 4°C. After incubation, cells were washed once in PBS/1% BSA, resuspended in 1% paraformaldehyde containing 1 g/ml 7-AAD (Sigma) and analyzed by flow cytometry. Treatment with goat-anti-mouse Ig PE conjugated served as control staining.
Cytotoxicity assay Cytotoxic activity was measured in a 51
Cr-release assay. Briefly, varying numbers of effector cells were added in triplicate to 96-well microtiter plates (100 l per well), followed by the addition of 2500 target cells (100 l) per well. The target cells were labeled with 50 Ci 51 Cr per 0.5 × 10 6 cells for 2 h at 37°C. At the end of the 4-h incubation period (37°C and 5% CO 2 ), supernatants were collected by using a Skatron harvesting system (Skatron, Lier, Norway) and counted in a gamma-counter (Wallac, Breda, The Netherlands). Percentage specific lysis was calculated as follows: ((test counts − spontaneous counts)/(maximum counts − spontaneous counts)) × 100%. Unless otherwise indicated four effector target cells (E/T) ratios were tested (60, 20, 6.7 and 2.2).
Measurement of lymphokine production
To determine lymphokine production by gene-transduced human T lymphocytes upon antigen stimulation, 6 × 10 4 gene-transduced human T lymphocytes were cultured for 24 h either in the presence or absence of 2 × 10 4 adherent tumor cells in RPMI culture medium containing 360 IU/ml rIL-2. Supernatant was harvested and levels of TNF-␣ and IFN-␥ were measured by ELISA (Medgenix, Fleuris, Belgium) according to the suppliers' specifications.
